

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Ali Andalibi, Ph.D., Program Director and Head of the Therapeutics and Diagnostics Section, National Cancer Institute's SBIR Development Center	3
Bill Barber, President, Maverick Angels	4
Mark Benedict, Ph.D., Partner, Knobbe Martens	5
Cesar Blanco, Ph.D., Head of Engineering and Project Management, AMI – USC	6
Bruce Blomstrom, Member, Pasadena Angels	7
Joseph Boystak, President and CEO, Brightwaters Capital LLC	8
Mike Bryan, Partner, Ernst & Young LLP	9
Ron Carlson, Senior Vice President, USI	10
Rajendra V. Deshpande, Ph.D., Senior Director, Emerging Technologies Corporate Office of Science and Technology (COSAT), Johnson & Johnson	11
Thomas Duk, Ph.D., Associate, Davis Wright Termaine	12
Ed Ellsworth, Director Corporate Alliances and Business Development, Beckman Coulter, Inc.	13
Jack Garza, Relationship Manager, Silicon Valley Bank	14
Nathalie Gosset, Manager of Marketing and Business Development, AMI – USC	15
Paul M. Grand, Managing Director, Pacific Coast Office Research Corporation Technology	16
Mark Greenfield, Partner, Blank Rome	17
Winston Z. Ho, Ph.D., CEO, Maxwell Sensors	18
Dave D. Hood MS, MBA, PMP, President, DH3 & Associates	19
Jack Judy, Ph.D., Program Manager, Microsystems Technology Office (MTO) Defense Advanced Research Projects Agency (DARPA).....	20

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Perry Karsen, COO, Celgene	21
Jerry Knotts, President and CEO, California Coast Venture Forum	22
Connie Koch, Executive Director, Keiretsu Forum	23
Mohammad E. Kondri, MPH, MIS/MBA, Trade Commissioner, International Business Development Officer Consulate General of Canada	24
Joel Kotkin, Author, Speaker and Futurist	25
Jason Lawson, Partner, Moss Adams LLP	27
Seth Levy, Partner & Co-Chair, Life Sciences Practice, Davis Wright & Termaine	28
William A. Lewis, CPCU, CIC Executive Vice President, Bolton & Company	29
Traci Libby, Director of Corporate Development, Life Technologies	30
Monty Mars, Director of Business Development, Edwards Lifesciences	31
Gregory Milman, Ph.D., Director of the Office for Innovation and Special Programs, National Institute of Allergy and Infectious Diseases (NIAID)	32
Russell W. Olson, Senior Principal Advisor, Regulatory & Clinical Institute, Inc.	33
Robert H. Raynor, Ph.D., Director, Corporate Business Development, Beckman Coulter, Inc.....	34
William Savin, Ph.D., Investor, Maverick Angels.....	35
Frank M. Singer, Founder and Former President, Tech Coast Angels	36
John W. Smither, Chief Financial Officer, Kythera Biopharmaceuticals	37
Bill Sturges, Partner, Moss Adams	38
Alex Suh, Managing Director, California Technology Ventures	39
Michael A. Swit, Vice President, Te Weinberg Group	40
Anne Tomalin, President and CEO, I3 CanRge Inc.	41
Josué Villalta, Partner, Knobbe Martens.....	42
Kevin Walsh, Interim Director Employee Training Institute, College of the Canyons	43
Stephen Williams, Ph.D., President & Chief Business Officer, Bench International.....	44
Michael Wise, Partner, Perkins Coie.....	45
Allan Wolfe, M.D., Former General Partner, UV Partners	46

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Ali Andalibi, Ph.D.

**Program Director and Head of the Therapeutics and Diagnostics Section
National Cancer Institute's SBIR Development Center**

Ali Andalibi is a molecular biologist and geneticist by training with extensive experience in both academia and industry. He received his Ph.D. from the UCLA department of Microbiology and Molecular Genetics and later joined the faculty in the UCLA department of Medicine. After leaving UCLA, he was involved in several early stage biotechnology companies. He then joined the House Ear Institute (HEI), where he served as the Director of New Technology and Project Development and was also an adjunct Assistant Professor of Otolaryngology, at the University of Southern California, School of Medicine. Dr. Andalibi then joined the National Science Foundation as a Program Director in the Division of Industrial Innovation and Partnerships, where he oversaw the NSF's medical biotechnology SBIR/STTR grant portfolio. Dr. Andalibi is currently a Program Director and heads the Therapeutics and Diagnostics Section in the National Cancer Institute's SBIR Development Center.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

**Bill Barber
President
Maverick Angels**

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Mark Benedict, Ph.D.
Partner
Knobbe Martens

Mark Benedict is a partner with Knobbe, Martens, Olson & Bear, LLP in the firm's Orange County office. He specializes in patent prosecution and strategic intellectual property portfolio management for pharmaceutical, biotechnology and life science clients.

Dr. Benedict's practice includes patent prosecution, counseling on patent infringement, validity and licensing issues, management of patent and other intellectual property assets, intellectual property due diligence studies and related counseling for investors. He currently represents clients in a wide range of technological areas, including pharmaceuticals, biotechnology, life sciences and medical devices. He also represents a number of foreign associates in procuring U.S. patent protection for their clients in the pharmaceutical and biotechnology areas.

Prior to joining the firm, Dr. Benedict worked as a Research Assistant Professor of Pediatrics at the State University of New York, Upstate Medical Center, where he conducted basic and clinical research, under grants from the NIH and the American Heart Association, on the molecular and biochemical mechanisms of hormone and growth factor regulation of vascular smooth muscle cell proliferation, differentiation and aging. Prior to joining the faculty, he worked at the SUNY medical school as a post-doctoral research fellow in Pediatric Endocrinology. During his tenure at SUNY, Dr. Benedict published and spoke extensively in the areas of endocrinology and aging.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Cesar Blanco, Ph.D.
Head of Engineering and Project Management
AMI – USC

Cesar Blanco has more than 15 years of experience in bioscience research and research administration in the cellular biology of neuromuscular systems, image processing, motor control and neuroendocrinology. He received a B.A. in Biology and his Ph.D. in Anatomy and Cell Biology from UCLA. While employed as a Staff Research Associate and Space Planner at UCLA, he was a key member of a UCLA/Jet Propulsion Laboratory team that developed an image analysis system for the measurement of enzyme activity in tissue sections. He was primarily responsible for the development of the biochemical techniques and coordinated the image processing software development. He returned to UCLA in 1987 to complete a Ph.D. in Anatomy and Cell Biology. After completing a fellowship at the UCLA Brain Research Institute in 1995, he accepted a Faculty position in the Department of Biokinesiology and Physical Therapy at USC. He was the Director of the Cellular Biokinesiology Laboratory where he led an NIH sponsored research team investigating the physiologic and cellular effects of anabolic steroids on respiratory motor control. He joined AMI-USC in 2003 as a Project Manager and Research Administrator. In December 2007, Dr. Blanco completed the UCLA Anderson School of Management's Executive Program in General Management.

Dr. Blanco's current responsibilities include: the management and allocation of engineering and project management resources and the administrative oversight of AMI-USC's Information Systems.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Bruce Blomstrom
Member
Pasadena Angels

Mr. Blomstrom has extensive working knowledge of the pharmaceutical and biotechnology industries. He is currently President of the Pasadena BioScience Collaborative, an incubator for early stage life science companies. Mr. Blomstrom is also an advisor to Infinite Biomedical Technologies, a medical device company and to MedRule, an enterprise software firm servicing providers and medical groups. He was the first Chairman of Nanostream, a manufacturer of microfluidic drug discovery instruments and director of Chemokine, a biotechnology company developing chemokine and cytokine based drugs. Mr. Blomstrom is also a Director of the Southern California Biomedical Council.

Previous positions include: President NMC Homecare, a division of Fresenius Medical Care; President and CEO CliniShare Inc., a division of UniHealth; President and CEO Guardian Products, a division of Sunrise Medical Inc; Vice President Whittaker Corp.; Senior Vice President of Alpha Therapeutics; several executive positions at Abbott Laboratories including Director of Corporate Planning, Executive Managing Director, Nippon Abbott Japan and General Manager South Africa; Assistant Secretary, Ministry of Commerce and Industry, Uganda, East Africa.

Mr. Blomstrom is a Trustee of the Pacific Asia Museum, a Director of the Pasadena Symphony, and a member of the Pacific Council on International Affairs. He is also active in several MIT alumni organizations. He has B.S. and M.S. degrees from the Massachusetts Institute of Technology.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Joseph Boystak
President and CEO
Brightwaters Capital LLC

Joseph Boystak is President and CEO of Brightwaters Capital LLC, a Los Angeles–based venture capital firm specializing in life sciences, nanotechnology and clean technology, with a particular emphasis on funding and commercializing academic research from colleges and universities. He is currently co-founder and chairman of WaterStyle Holdings Inc., a spin-out from the University of California, Los Angeles, in water technology; of NanoPacific Holdings Inc., a spin-out from UCLA in nanotechnology; of Bruin Biometrics Inc., a spin-out from UCLA in medical devices; and a board member of Exosome Diagnostics Inc., a spin-out from Harvard University in diagnostics. Boystak serves on the Health Advisory Board at the Johns Hopkins Bloomberg School of Public Health. He received a bachelor's degree from Boston University and a master's degree from the Johns Hopkins Bloomberg School of Public Health.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Mike Bryant
Partner
Ernst & Young LLP

Mike Bryant is a tax partner in the Los Angeles office of Ernst & Young, and has been a resident of Southern California for the last 16 years. He has 30 years of experience serving the Federal, International, State, and local tax needs of public and private corporations and partnerships, specializing primarily in industries such as financial services, health sciences, and private equity.

Mike's clients include healthcare companies, such as Prospect Medical, Worldwide Clinical Trials, Cedra, StemCyte, and Second Sight, and private equity companies, such as Ares Management, Brentwood Associates, and Aurora Capital.

Mike is a certified public accountant, licensed to practice in the states of California and Texas. Prior to coming to Southern California, Mike worked in Washington D.C. in the National Tax Practice working closely with the Treasury Department and the IRS National Office.

Mike is a member of the American Institute of Certified Public Accountants, and has served on AICPA tax subcommittees of the Tax Division in Washington, D.C..

Mike has published articles on tax planning in The Journal of Bank Taxation, The Tax Adviser, and Corporate Taxation, and has been quoted in many industry periodicals, including the Wall Street Journal, USA Today, Money Magazine, and The American Banker.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Ron Carlson
Senior Vice President
USI

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Rajendra V. Deshpande, Ph.D.
Senior Director, Emerging Technologies
Corporate Office of Science and Technology (COSAT), Johnson & Johnson

Raj Deshpande joined COSAT in May 2010 as a Senior Director in Emerging Technologies. Based in California, he is responsible for identifying on the West Coast the early, innovative approaches to substantially improve human healthcare.

Raj comes to COSAT after a 2-year leadership role at Ethicon Endo-Surgery (EES) where he was responsible for the Clinical Affairs organization to develop and execute global clinical strategies for products and technologies. Areas of focus included intervention of obesity, metabolic diseases, gastro-intestinal ailments, and cancer with the use of mechanical and energy-based devices.

Prior to joining Johnson & Johnson, Raj held a succession of leadership roles at Amgen from 1997 to 2008. He was a member of the research teams and global product strategy teams in oncology, inflammation, metabolic disorders, and neuroscience, advancing drugs, biologics, and combination products from innovation to commercialization. His roles within Research, Development, Regulatory Affairs, and R&D Strategic Operations assisted in advancing product pipeline, broadening technology portfolio, and expanding international alliances.

Prior to joining Amgen, Raj was a scientist at Pharmacia & Upjohn (now Pfizer) from 1995 to 1997, where he carried out anti-inflammatory drug discovery, and integrated large and small molecule discovery platforms.

From 1992 to 1995, Raj was a post-doctoral research scientist at Memorial Sloan-Kettering Cancer Center, where he conducted discovery research in hematology, oncology, and molecular cell biology.

Raj has authored 11 worldwide and international patent applications on human therapeutics, and has several publications in peer-reviewed scientific journals. He has a Ph.D. in Immunology, a M.S. in Medical Microbiology, and a B.S. in Microbiology.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Thomas Duk, Ph.D.
Associate
Davis Wright Termaine

Thomas Duk performs patent prosecution, research, and freedom-to-operate analyses in the firm's intellectual property practice. He earned a doctorate in molecular biochemistry and biophysics from the Illinois Institute of Technology and received his bachelor's degree in microbiology from the University of California, Santa Barbara—where he also performed research for three years. In addition to his scientific background and research experience, Tom offers the valuable business perspective he gained while serving as a C-level executive for several small to mid-sized companies, prior to joining Davis Wright.

Additional Qualifications

- Executive Vice President of Operations, Lifestyles AT&T
- Contract Attorney, Blanchard & Associates
- Marketing & Business Development Advisor, IP & Technology, Sonnenschein Nath & Rosenthal LLP

Education

Ph.D., Molecular Biochemistry and Biophysics, Illinois Institute of Technology, 2007

- Research Fellowship
- Outstanding Teaching Assistant Award

J.D., Loyola University Chicago School of Law, 2002

- Illinois Bar Association Scholarship
- Loyola University of Chicago Honors Scholarship
- Baker & McKenzie Law Scholarship

B.S., Microbiology, University of California, Santa Barbara, 1999

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Ed Ellsworth
Director Corporate Alliances and Business Development
Beckman Coulter, Inc.

Ed Ellsworth is the Director Corporate Alliances and Business Development at Beckman Coulter. He has over 20 years of experience base in business development, marketing, technical operations and general management in the life sciences, imaging and medical device industry.

Mr. Ellsworth received his bachelor's degree in Electrical Engineering and Computer Science and MBA both from California State Polytechnic University-Pomona.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Jack Garza
Relationship Manager
Silicon Valley Bank

Jack Garza is a Relationship Manager on Silicon Valley Bank's Early Stage team in Los Angeles. The Early Stage team focuses on the banking needs of Life Science, Technology, and Cleantech companies from startup through Revenues of \$75MM.

Mr. Garza started his career at Silicon Valley Bank in 2004 working on the Corporate Finance and Software teams in the San Francisco Bay Area. Prior to joining SVB, Mr. Garza was an Assistant Vice President at City National Bank and started his career with U.S. Bank. He earned his B.S. in Economics & Business Administration with an Honors Concentration in Financial Services from Saint Mary's College of California.

Through its 27 domestic offices and operations in England, India, Israel, and China, SVB Financial Group (NASD: SIVB) provides domestic and international commercial banking, investment management, and valuation services to technology companies at all stages of their life cycles – from startup to public. With over 10,000 clients, SVB is the preferred partner for more than half of the venture-backed technology companies in the US.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Nathalie Gosset
Manager of Marketing and Business Development
AMI – USC

Nathalie Gosset has 20 years experience in the development and commercialization of technology-based products (medical, oil and gas instrumentation, and telecom). The first 15 years of her career were in Engineering, starting from design, continuing onto the management of large engineering programs, and finishing with several start up companies requiring Engineering makeover (turnaround). Her previous job was Vice President of Engineering at Sabeus, Inc. Ms. Gosset has received several awards for professional excellence and innovative leadership. At Alcatel, she received an Outstanding Achiever Award and five Quality Cups (a prestigious recognition at Alcatel).

At AMI, Ms. Nathalie Gosset is responsible for Marketing and Business Development. She develops product specific strategic business strategies for each new invention sponsored by AMI. Ms. Nathalie Gosset is well connected to the medical and bioengineering community. She is a member of several medical advisory, board of directors, as well as venture firm review committees. She was elected the 2007 Northern America Representative of the international IEEE Engineering in Medicine and Biology Society. She recently received the 2005 Outstanding IEEE-Engineering in Medicine and Biology Society Chapter Award, a global recognition. She holds a BSEE from ISEP (Paris, France); MS in Telecommunications (University of Colorado, Boulder, CO); MBA (University of St. Thomas, St. Paul, MN).

12th SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Paul M. Grand
Managing Director, Pacific Coast Office
Research Corporation Technology

Paul Grand represents RCT and the RCT BioVentures early-stage investment program to start-up companies and research institutions on the west coast of the United States. He has built, operated, recruited management and raised financing for eight high technology, medical device and biotechnology companies. He is a director of VasoNova Inc. and a manager of RCT's investment in Corion Medical Ventures.

Professional Experience

Research Corporation Technologies
Managing Director, 2008–present
Director, 2005-2007

AlamX Inc.
Consultant, August 2004-January 2005

Imagine Pharmaceuticals Inc.
Co-founder & Vice President, Operations, November 2001-July 2004

MicroSurgeon Inc.
CEO, November 2001-January 2003

Tarleton Technologies Inc.
Founder, CEO, December 2000-May 2001

AdExchange Inc. (acquired by Tarleton Technologies Inc.)
Founder, CEO, May 1999-November 2000

Word of Net Inc. (acquired by Inceptor Inc.)
CEO, January 1998-April 1999

NetCount LLC (acquired by I/PRO Inc.)
Founder, Chairman, August 1995-November 1997

Digital Planet Inc. (acquired by IXL Enterprises Inc.)
Founder, CEO, October 1994-August 1995

The Berkeley Group
VP Business Affairs, CFO, October 1990-October 1994

Taste of Nature Inc.
Co-founder, August 1990-August 1991

Board Membership

VasoNova Inc., 2007-present

Education

Tufts University, B.A.

Contact

pgrand@rctech.com

November 4, 2010



Page 16 of 46

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Mark Greenfield

**Partner
Blank Rome**

Mark Greenfield focuses his practice on corporate finance. He concentrates on helping clients with:

- mergers and acquisitions
- public offerings and private placements
- syndications
- corporate formations
- corporate reorganizations
- corporate governance
- general corporate counseling

Mr. Greenfield represents clients in a broad range of industries including energy, technology, biotechnology, software, healthcare, medical devices, pharmaceutical, manufacturing, gaming, hospitality, entertainment, and financial services. He also regularly provides expert testimony in the areas of corporate governance and healthcare, and he has served on numerous corporate boards, including audit committee assignments.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Winston Z. Ho, Ph.D.
CEO
Maxwell Sensors

Winston Ho has been working with lab-on-a-chip, microsensors, biosensors, microfluidics, and biomedical instruments for more than 20 years. He has extensive experience in developing miniaturized biosensors and compact diagnostic devices. He is responsible for developing innovative technologies and commercial products for clinical diagnostics, such as Barcoded Magnetic Beads (BMB), KetoneMax, LuminMax, FS-Scanner, chemiluminescence bio-disc, Photodynamic Diagnostic (PDD) System, 3-D endoscope without goggle, etc. Dr. Ho has authored more than 50 published papers on clinical diagnostics, optoelectronics, biosensors, optical imaging and detection. He has 11 issued and 9 pending patents. He served as an SPIE program committee and NIH grant review committee. He obtained his M.S. (Biochemistry) and Ph.D. (Biophysics) from Arizona State University, and then worked as a postdoctoral fellow at Columbia University (Chemistry) in New York and a Research Scientist at University of Arizona (Optical Science Center).

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Dave D. Hood MS, MBA, PMP
President
DH3 & Associates

Dave Hood is President of DH3 & Associates, a consulting company focusing on performing technology assessments and developing strategies for product development and business development.

For more than five years, Mr. Hood also served as a Senior Advisor for the Principal Assistant for Acquisitions at the US Army Medical Research and Materiel Command. Prior to founding DH3 & Associates, Mr Hood was the Co-Founder and President of Integrated Medical Systems where he was also co-inventor of the company's core product line. Prior to being selected to guide this successful spin-out from Northrop Grumman, he served as a Senior Program Manger successfully guiding the development and deployment of various integrated sensor systems for high performance aircraft, missiles, and satellites including the stealth bomber and the Global Positioning Satellites (GPS). He also guided successful projects pioneering intelligent transportaion systems and high performance fuel efficient, environmentally friendly engines and brake systems for automobiles and motorcycles.

Mr. Hood has worked with the US Congress and European governments to sponsor funding for innovative medcial products. He holds 3 patents and has been the stimulus for more than 2 dozen. He has published and presented extensively in the US and Europe. He has also taught graduate school courses in Project Management, Business Management, Operations Management and Entrepreneurship.

He is a certified Project Management Professional and has received executive training from the University of Southern California and the Massachusetts Institute of Technology.

He is also Chairman of the Long Beach Sailing Foundation, a 501c organization that owns a fleet of matched sailboats used for team building experiences as well as amateur and professional racing events including the Congressional Cup. He is also Head Coach for a club softball team that provides inner city and disadvantaged teenage girls an opportunity to learn the fundamentals of teamwork and sportsmanship.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Jack Judy, Ph.D.

**Program Manager, Microsystems Technology Office (MTO)
Defense Advanced Research Projects Agency (DARPA)**

Jack Judy is a Program Manager in the Microsystems Technology Office (MTO) of the Defense Advanced Research Projects Agency (DARPA), Arlington, VA; he is serving in this capacity while on leave from his faculty position as an Associate Professor in the Electrical Engineering Department and Biomedical Engineering Interdepartmental Program at the University of California, Los Angeles. He received the B.S.E.E. degree with Summa cum Laude honors from the University of Minnesota, Minneapolis, MN, in 1989, and the M.S. and Ph.D. degrees from the University of California, Berkeley, CA, in 1994 and 1996 respectively. His doctoral research concentrated on the merger of thin-film magnetic-recording head fabrication techniques and technologies with those used in the IC industry, to produce novel ferromagnetic MEMS devices with silicon-based flexures.

Dr. Judy worked for Silicon Light Machines, Inc., Sunnyvale, CA, a startup company commercializing a MEMS-based optical-projection system for digital-display applications, from 1996 to 1997. He joined the faculty of the Electrical Engineering Department at the University of California, Los Angeles, in 1997, where he is currently an Associate Professor. While at UCLA he served as the Director of the NeuroEngineering Program, the Nanoelectronics Research Facility, and the Microfabrication Laboratory. Dr. Judy received the prestigious NSF CAREER Award and the Okawa Foundation Award in 1999 and 2002, respectively.

Dr. Judy is presently interested in the following fields:

- Reliable High-Performance Neutral-Electronic Interfaces
- High-Density Energy Conversion Microsystems
- High-Performance Mesoscale Actuators
- Miniature High-Performance Power Converters

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Perry Karsen
COO
Celgene

Perry Karsen currently serves as Chief Operations Officer at Celgene Corporation. Most recently, Mr. Karsen served as President and Chief Executive Officer at Pearl Therapeutics.

From 2004-2009, Mr. Karsen was Senior Vice President and Head of Worldwide Business Development at Celgene and was also responsible for emerging businesses as President, Asia/Pacific Region.

Previously, he was Senior Vice President, Business Development at Human Genome Sciences. Earlier in his career, he held positions including Vice President, Strategic Business Analysis and Development, Bristol-Myers Squibb; Senior Vice President Marketing and Sales, Zimmer, Inc.; Director, Business Development and Representative Director, Japan, at Genentech and various domestic and international roles with Abbott Laboratories. Additionally, Mr. Karsen was a General Partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices.

Mr. Karsen serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO).

Perry has a Masters of Management degree from Northwestern University's Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Jerry Knotts
President and CEO
California Coast Venture Forum

Jerry Knotts is the President/CEO of the California Coast Venture Forum and President of J.E. Knotts & Associates. He has more than 30 years successful experience in small, medium and large sized defense and aerospace low and hi-technology companies. He served as Vice-President/General Manager, Defense Electronics Div, California Microwave and Vice-President, American Nucleonics Corporation. He serves as a member of the Board of Counselors, California Lutheran University School of Business; a member of the SoCalBio Investor Conference Company/Company Screening Board; and a mentor for the LARTA Institute.

Jerry has notable achievements in general business management, strategic planning, and business development. As a consultant, he serves on numerous Corporation Boards and provides strategic and financial planning services to small and medium sized companies. His academic background includes a BSEE (Electrical Engineering) from Penn State University; an MBA from Auburn; and graduate of the Defense Systems Management College (DSMC), Industrial College of the Armed Forces (ICAF), and Air War College. Jerry is a Senior Life Member of the IEEE and a registered Professional Engineer

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Connie Koch
Executive Director
Keiretsu Forum

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Mohammad E. Kondri, MPH, MIS/MBA
Trade Commissioner, International Business Development Officer
Consulate General of Canada

Mohammad Kondri is Trade Commissioner and International Business Development Officer for Life Sciences & Med Tech at the Consulate General of Canada in Los Angeles. He is responsible for advising the Canadian life sciences industry on innovation and investment issues and developing partnerships in the biotech industry and institutions in Southern California. He has over 25 years of basic research, pharmaceutical development, technology evaluations, corporate management, and international partnership development experience in the field of biomedical sciences with non-profit research institutions, pharmaceutical industry and government.

Prior to joining the Canadian Consulate, he served as Associate Director of Operations in the Bio-Analytical and Immunology Services laboratories at Covance Pharmaceuticals development Inc. Before Covance, he worked as a Senior Research Scientist and Corporate Technology Transfer liaison at Bristol-Myers Squibb Pharmaceutical Research Institute, Fred Hutchinson Cancer Research Center and Howard Hughes Medical Institute.

He has authored and co-authored several publications in the areas of gene expression, DNA manipulations, biopharmaceutical drug development for cancer and immunological diseases, and contributed to the development and commercialization of five drug candidates. He holds several patents with potential drug development applications. He has a MPH in Molecular Microbiology and Public Health from Washington State University and MIS/MBA in Technology Management from the Steven's Institute of Technology.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Joel Kotkin
Fellow in Urban Futures
Chapman University

An internationally-recognized authority on global, economic, political and social trends, Joel Kotkin is the author of a new book, *THE NEXT HUNDRED MILLION: America in 2050*, published in February by The Penguin Press. The book explores how the nation will evolve in the next four decades. It has received rave reviews from *The New York Times*, *Wall Street Journal*, *the Globe and Mail*, and *National Public Radio*.

His previous, also critically acclaimed book, *THE CITY: A GLOBAL HISTORY*, was published in 2006 by Random House/Modern Library, with editions published in China, Spain, UK and the British Commonwealth, Japan and Korea.

Mr. Kotkin is Distinguished Presidential Fellow in Urban Futures at Chapman University in Orange, California and an Adjunct Fellow with the Legatum Institute based in London, UK. A highly respected speaker and futurist, he consults for many leading economic development organizations, private companies, regions and cities. Joel is also a Senior Fellow with the Center for an Urban Future in New York City; and a Senior Consultant with the Praxis Strategy Group in Fargo, North Dakota.

Described by the *New York Times* as America's "uber-geographer," for over three decades Mr. Kotkin has been one of the nation's most prolific and widely-published journalists. He currently writes the weekly "New Geographer" column for Forbes.com.

He previously wrote the monthly "Grass Roots Business" column in *The New York Times'* Sunday Business section and served as West Coast Editor for *Inc. Magazine* for five years and continues to contribute to the publication. His work also appears in *The Wall Street Journal*, *Newsweek*, *The Washington Post*, *The American*, *The Daily Beast* and the *American*.

He has also worked extensively in television, including on documentaries for both German television and Los Angeles public television. He served as Business Trends Analyst for KTTV/Fox Television in Los Angeles, where, in 1994, he won the Golden Mike Award for Best Business Reporting on the changing dynamics of the entertainment industry.

Mr. Kotkin is also the author of *THE NEW GEOGRAPHY*, How the Digital Revolution is Reshaping the American Landscape (Random House, 2000); and *TRIBES: How Race, Religion and Identity Determine Success In the New Global Economy*, (Random House, 1993) which traces the connection between ethnicity and business success — how in-group loyalties are becoming the driving force in the new global economy.

TRIBES has been published in Chinese, Japanese, Arabic and German. He co-authored *THE THIRD CENTURY — America's Resurgence in the Asian Era*, (Crown, 1988). This title was translated into Japanese and Chinese, with a special English edition published for the Pacific Rim. His first book, *CALIFORNIA, INC.* (Crown, 1982) dealt with California's links to the emergent powers of the Pacific Rim. Kotkin's novel, *THE VALLEY*, was published in 1983 by Bantam Books.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Over the past decade, Mr. Kotkin has completed studies focusing on several major cities, including New York; St. Louis; Phoenix; Laval, Quebec's second largest city; Los Angeles and Houston. In association with the Planning Center and the La Jolla Institute, in 2006 he completed a year-long study on the future of suburban development. His most recent published studies have focused on the economic revitalization for Salinas, California; the future of New York's middle class; an economic vision for the City of Ontario, California and a major study for the La Jolla Institute on the Four Corners region of Southern California. Last month he helped write a report with the Praxis Strategy Group called "Enterprising States" for the US National Chamber Foundation. His latest report, an international study on urban upward mobility for the Legatum Institute in London will be released in late May. It will focus on developments in London, Mumbai and Mexico City.

Mr. Kotkin lectures widely in the United States, UK, Asia, Australia and Europe and is sought after as a speaker by major business and financial organizations. In August, he will travel to Denver to accept the Gene Burd Award for best urban reporting.

Mr. Kotkin attended the University of California, Berkeley. A native New Yorker, he has lived in California since 1971. Mr. Kotkin lives in the Valley Village area of Los Angeles with his wife, Mandy Shamis, and two daughters.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Jason Lawson
Partner
Moss Adams LLP

Jason Lawson brings 15 years of accounting and consulting experience to public and private companies in the life sciences, technology and consumer products industries. Prior to Moss Adams, Jason served as a Professional Accounting Fellow at the Securities and Exchange Commission in Washington, D.C., where he was one of three individuals selected nationally to participate as a Professional Accounting Fellow in the Division of Corporation Finance. While at the SEC, he reviewed registration and periodic filings primarily of pharmaceutical, biotechnology and healthcare related public companies. In addition, Jason periodically writes US CPA exam questions for the AICPA, and has participated in the Staff Advisory Group which provided recommendations to the AICPA on integrating International Financial Reporting Standards into the US CPA exam.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Seth Levy

Partner & Co-Chair, Life Sciences Practice

Davis Wright & Termaine

Seth Levy, a patent attorney with a background in biological engineering, focuses on supporting technology transfer programs at academic institutions and working with technology-based companies across a range of matters. Seth represents clients in patent procurement, licensing and enforcement; in the coordination of complex research arrangements and resolution of related disputes; and in the negotiation of commercial transactions involving intellectual property.

Practice Highlights

- Manages patent procurement for innovations in a variety of technical fields, including biotechnology and life sciences
- Represents academic institutions in licensing intellectual property to the private sector and in structuring sponsored research agreements, material transfer agreements and inter-institutional agreements with nonprofit and for-profit collaborators
- Represents emerging companies in intellectual property licensing and acquisitions
- Supports intellectual property due diligence in connection with mergers and acquisitions for biotechnology and consumer products companies
- Serves as outside general counsel for early-stage technology companies

Professional Recognition

- Named as one of "America's Leading Lawyers for Business" in Life Sciences: Commercial (California) by Chambers USA, 2009
- Selected to "Southern California Rising Stars," Law & Politics, 2008-2009
- Inaugural recipient, Paul Davis Memorial Award for outstanding leadership in pro bono work, University of Southern California Law School, 2004
- Jack Berman Award of Achievement, recognizing a young lawyer who has provided outstanding service to the legal profession and public, as well as dedication to issues of concern to new and young lawyers,
- California State Bar, 2005
- Star of the Year award, 2002, 2006 and 2009; Star of the Quarter award, 2004, 2005 and 2007; ABA Young Lawyers Division
- Wiley W. Manuel Award for Pro Bono Legal Services, four-time recipient, California State Bar

Education

- J.D., University of Southern California Law School, 2001
- B.S., Agricultural & Biological Engineering, Cornell University, 1998, cum laude

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

William A. Lewis CPCU, CIC
Executive Vice President
Bolton & Company

Bill Lewis is a graduate of California State University at Los Angeles and San Diego State University.

Bill has been in the insurance industry since 1981 and has been with Bolton & Company since 1989. He has earned the Chartered Property and Casualty Underwriter and Certified Insurance Counselor designations.

Bill is responsible for developing new clients for the company and providing Risk Management and insurance programs for his existing clients. His clients come from various industries, such as construction, high-tech, biotech and other fields. Bill helps these clients with all coverages including difficult risks requiring Professional Liability coverage or those that fit in an alternative risk transfer mechanism such as captives, deductible plans and self insured solutions.

Bill has contributed to the growth of Bolton & Company through his insurance expertise, specifically geared toward technology-based risks, such as software development and multimedia companies, biotechnology risks, Directors and Officers Liability, and Intellectual Property protection, including copyright and trademark exposures and patent infringement coverage. Bill has utilized this experience to assist in the development of local incubator and start up companies.

In 2009 Bolton & Company has formally created a Technology Practice to take advantage of the expertise of the firm in the high tech and life science arenas. The group will work with such clients to develop and refine risk management programs and place coverage ranging from products and clinical trials liability to directors and officers coverage. Spurring the creation of this Technology Practice was the appointment of Bolton as the Southern California broker representative of Tech Assure, a national partnership of similar firms specializing in this industry. Bill leads this practice and takes advantage of Bolton's memberships in groups such as the Southern California Biomedical Council and BIO.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Traci Libby
Director of Corporate Development
Life Technologies

Traci Libby is Director of Corporate Development at Life Technologies in Carlsbad, CA.

Ms Libby has responsibilities for global technology inlicensing and non-M&A transactions. Her team identifies and assesses technologies with applicability to Life Technologies' research tools and bioproduction portfolio of over 35,000 products, which currently includes over 1,600 patents and licenses and well-recognized life science brands such as Molecular Probes, Gibco, and Dynal, among others.

In addition to the many acquisitions accomplished by Life Technologies' corporate development team during her years at Life Technologies, Traci's group currently concludes approximately 150 non-M&A deals per year, including patent license and equity agreements, collaborative agreements, sponsored research, and co-marketing transactions.

Prior to her tenure at Life Technologies, Traci was head of new product development and a senior product manager at Chemicon International (acquired by Millipore), manager of global technical support and member of product development teams at Calbiochem (now EMD), and laboratory director at a contract viral and interferon bioassay services CRO.

Traci obtained her undergraduate degree in biochemistry at the University of California, San Diego, and did her graduate studies in molecular and cell biology at San Diego State University.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Monty Mars
Director of Business Development
Edwards Lifesciences

Monty Mars is currently Director of Corporate Development at Edwards LifeSciences. Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Mr. Mars has extensive experience in licensing, partnerships and mergers and acquisitions in the life science industry.

Mr. Mars holds a BS in Biochemistry from the University of California at Davis, a JD from the University of Southern California and an MBA from the Wharton School of Business.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Gregory Milman, Ph.D.
Director of the Office for Innovation and Special Programs
National Institute of Allergy and Infectious Diseases (NIAID)

Gregory Milman manages the \$100 million NIAID small business programs and is acclaimed for his advice on NIH grant preparation and research funding.

Dr. Milman was Assistant Professor of Biochemistry at the University of California, Berkeley from 1970-1976, Associate Professor of Biochemistry and Immunology at Johns Hopkins University from 1976-1988, and visiting Professor in Honors at the University of Maryland College Park from 1997-2000. In 1985, he obtained NIH SBIR funding to start a biotechnology company focusing on viral diagnostics. From 1988-1999, Dr. Milman managed the NIAID \$70 million basic AIDS research program. He established the NIH Centers for AIDS Research (CFARs) and the NIH AIDS Reagent Program. From 1997 to 2000, Dr. Milman organized the NIH Bioengineering Consortium (BECON) and acted as its first Executive Secretary. In 2000, Dr. Milman was on the NIH staff in President Clinton's White House Office of Science Policy.

Dr. Milman has served on the Board of Directors of the Biotechnology Industry Organization Council of Biotechnology Centers, the Maryland Governor's Commission on the Development of Advanced Technology Business, and the Advisory Board for the National Institute of Science and Technology (NIST) Advanced Technology Program (ATP).

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Russell W. Olson
Senior Principal Advisor
Regulatory & Clinical Institute, Inc.

Russell Olson is a Senior Principal Advisor at RCRI, Inc. He has over 25 years of experience in the medical device industry, 15 years of which have been with venture funded companies, focusing upon the areas of research, manufacturing, product development, quality systems and regulatory affairs. He has successfully gained multiple facility and product approvals in the United States and Europe including a PMA, multiple 510(k)'s, IDE's CE Marks and approvals for Quality Systems. Russ assists RCRI's clients with determining domestic regulatory strategies, drafting submissions, and negotiating their approval with the FDA. In addition, due to his significant experience with notified bodies and CE marking products, he provides guidance to medical device clients for CE certification to the MDD and AIMD directives; Technical File and Design Dossier preparation; Quality System design, certification, auditing, and compliance; and international product registration.

Russ holds a B.S. in Microbiology and Public Health. He has additional training in the areas of quality system auditing, and sterilization validations, sterile packaging testing, FDA and ISO compliance issues and negotiations. With his experience, Russ has acquired a complete understanding of product design/development, process validation, manufacturing, quality systems and regulatory requirements.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Robert H. Raynor, Ph.D.
Director, Corporate Business Development
Beckman Coulter, Inc.

Robert Raynor, Ph.D., is the director of the corporate business development group for Beckman Coulter, Inc., a global developer, manufacturer and distributor of diagnostic instrumentation for clinical laboratories. Over the past 6 years he has led a number of strategic acquisitions for the company and also headed integration teams for new acquired businesses. Dr. Raynor has a strong technical background having been responsible for development of more than 50 IVD products utilized in cancer and infectious disease monitoring. Dr. Raynor received his Ph.D. in Microbiology and Immunology from the Medical College of Georgia and an MBA from Florida Atlantic University. He has been with Beckman Coulter for more than 20 years having held leadership positions in product development, business development, and Investor Relations.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

William Savin, Ph.D.
Investor
Maverick Angels

William Savin is an investor with the Maverick Angels. He has more than 25 years of experience in biotechnology. Previously, Dr. Savin was the Vice President of Sales and Marketing Operations at Amgen and Senior Product Manager at Syntex.

Dr. Savin received a Ph.D. in Cardiovascular Physiology from Stanford University and a B.S./M.S. from the University of California, Davis.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Frank M. Singer
Founder and Former President
Tech Coast Angels

Frank Singer graduated with honors from Purdue earning a BSME and has an MBA from the University of South Florida and completed all course work towards a Ph.D. in Economics. He has teaching credentials in several technical and business disciplines. He holds several patents and has held executive positions at a number of Fortune 100 companies including Honeywell, General Dynamics, Becton Dickinson, and Microdot prior to acquiring several aviation related businesses. In 1986 he was awarded the first Entrepreneur of the Year award in Orange County for pioneering a joint venture in Mainland China.

Currently Mr. Singer sits on several boards, was a founder and past president of the Tech Coast Angels, past president of the Orange Coast Venture Group, is vice chair of TechAmerica's (formerly the AeA) Government Affairs committee, is on the Concordia College Dean's Advisory Board, and recently authored a book on business valuation.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

John W. Smither
Chief Financial Officer
Kythera Biopharmaceuticals

John Smither is responsible for all financial and administrative aspects of the company including financing, business planning and budgeting, tax and accounting and treasury. Prior to joining Kythera, he spent more than 9 years at Amgen, Inc. where he advanced rapidly through financial management positions for business units and subsidiaries based in Europe and the US. During his term as Chief Financial Officer of Amgen Europe, Smither directed financial planning, accounting, cost accounting, treasury, cash management and financial reporting under U.S. GAAP in 25 European countries.

Prior to Amgen, he was an audit partner at Ernst & Young, the Chief Financial Officer of several early stage industrial companies and a former member of the Board of Directors of Dompe Biotec S.p.A. Smither holds a BS in Accounting from California State University at Los Angeles. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants (AICPA), the California Society of Certified Public Accountants (CSCPA) and Financial Executives International (FEI).

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Bill Sturges
Partner
Moss Adams

Bill Sturges joined Moss Adams in 2006 with over five years of public accounting experience. He graduated from the University of Wisconsin, earned an M.B.A. from UC Davis, and received his Master's in Taxation from Golden Gate University (GGU). He currently acts as an Adjunct Professor of Taxation at GGU.

Bill focuses primarily on middle-market Manufacturing and Distribution clients.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Alex Suh
Managing Director
California Technology Ventures

Alex Suh is a founding Managing Director with California Technology Ventures, LLC, a Southern California venture capital firm that focuses its investments in the fields of Life Sciences and Information Technology. Alex is the managing director that invests in Life Sciences as well as Information Technology.

Alex is also a founding Managing Director with J.J. Jacobs Enterprises, LLC and Jacobs Capital Group, LLC, both Pasadena-based venture capital and fund-of-fund firms where he has invested in other venture capital funds globally that offer a strategic fit with California Technology Ventures.

Before co-founding Jacobs Enterprises, Jacobs Capital Group and California Technology Ventures, Alex was an entrepreneur starting several businesses, helped develop the first small business incubator in the San Gabriel Valley, managed several small business lending programs, consulted with nonprofits and cities on economic development projects and taught college in entrepreneurship, business and management.

His community involvement included past president to Villa Esperanza, a school for developmentally challenged persons; distinguished president for Kiwanis; Advisory board member for Women at Work and the Crippled Children's Society; Special Olympics coach and more.

Alex graduated with honors from the University of Denver's School of Business with a B.S.B.A. in Management.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Michael A. Swit
Vice President
Te Weinberg Group

Michael Swit is a Vice President at The Weinberg Group, where he develops and ensures the execution of a broad array of regulatory and other services to clients, both directly and through outside counsel. His expertise includes product development strategies, compliance and enforcement initiatives, recalls and crisis management, submissions and related traditional FDA regulatory activities, labeling and advertising, and clinical research efforts. Both his own practice and that of the firm encompasses not only drugs, biologics, and therapeutic biotech products, but extensive experience with device, IVD, and other life sciences companies, as well as those in the food and dietary supplement industries.

Mr. Swit has been addressing critical FDA legal and regulatory issues since 1984. His vast and multi-faceted experience includes serving for three and a half years, from 1990 to late 1993, as corporate vice president, general counsel and secretary of Par Pharmaceutical, a prominent, publicly-traded, generic drug company and, thus, he brings an industry and commercial perspective to his work with FDA-regulated companies. Mr. Swit then served for over four years as CEO of Washington Business Information, Inc. (now known as FDANews), a premier publisher of FDA regulatory newsletters and other specialty information products for the FDA-regulated community. His private FDA regulatory law practice has included service as Special Counsel in the FDA Law Practice Group in the San Diego office of Heller Ehrman White & McAuliffe and with the Food & Drug Law practice at McKenna & Cuneo, both in the firm's Washington office and later in San Diego. He first practiced FDA regulatory law with the D.C. office of Burditt & Radzius.

Mr. Swit has taught and written on a wide variety of subjects relating to FDA law, regulation and related commercial activities, including, since 1989, co-directing a three-day intensive course on the generic drug approval process and editing a guide to the generic drug approval process, *Getting Your Generic Drug Approved*. A former member of the Food & Drug Law Journal Editorial Board, Mr. Swit also has been a prominent speaker at numerous conferences sponsored by such organizations as RAPS, FDLI, and DIA. He earned his A.B., magna cum laude, with high honors in history, from Bowdoin College, and his law degree at Emory University School of Law. Mr. Swit is admitted to the D.C., Virginia and California bars.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Anne Tomalin
President and CEO
i3 CanRge Inc.

As President of i3 CanReg, i3's strategic regulatory services group, Anne Tomalin is responsible for providing strategic leadership for regulatory services provided by i3 to its clients. Prior to founding CanReg Inc, (the company's name until its acquisition by i3 in 2009) Anne spent 20 years working at Searle Pharmaceuticals. In the latter years, she worked as a business unit leader responsible for regulatory affairs, medical information, and government affairs. She has also worked for Hoffmann LaRoche and Wyeth within the area of regulatory affairs. During her career, Anne has been responsible for marketing applications across all therapeutic areas within Canada and in several therapeutic areas (including infectious disease) in the US. She is a recognized regulatory leader and frequently participates in policy development meetings with industry and government participants. Anne holds a BSc in chemistry, a BA degree in English, and a Regulatory Affairs Certification (RAC) in the US, Europe, and Canada.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Josué Villalta
Partner
Knobbe Martens

Josué Villalta is a partner with Knobbe, Martens, Olson & Bear, LLP in the firm's Los Angeles office. He specializes in patent protection, including patent prosecution, patent portfolio management, IP due diligence and general counseling on infringement issues. Mr. Villalta represents clients in a wide range of technologies, including medical devices. Prior to joining the firm, Mr. Villalta was a senior mechanical engineer with General Electric's Power Generation division, where he performed heat transfer and fluid dynamics analyses of commercial nuclear power plants under transient operating conditions.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Kevin Walsh
Interim Director
Employee Training Institute, College of the Canyons

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Stephen Williams, Ph.D.
President & Chief Business Officer
Bench International

Bringing over 18 years of experience from a roster of senior roles in the pharmaceutical and biotechnology industries, Steve Williams joined Bench in 1998.

After earning his doctorate in Pharmacology from Duke University, he worked with DuPont and DuPont Merck for 12 years, leading the imaging agents pharmacology and toxicology efforts in the discovery and development of Cardiolite and Neurolite.

Subsequently, he held positions in product management and new product planning for CNS drugs at DuPont and served as Medical Director for CNS Strategic Product Planning at Bristol-Myers Squibb. Steve also spent seven years in biotechnology, leading corporate development functions for two start-up companies, one of which was taken public.

In addition to overseeing Bench's business operations, Steve recruits in the areas of Research and Development, Business Development and Corporate Executives. He also provides expert consulting services in the area of business development and strategy.

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Michael Wise
Partner
Perkins Coie

Michael Wise is a partner and chairs Perkins Coie's China Intellectual Property practice. He focuses on patent matters in the life sciences industry. Michael serves as lead counsel in biotech litigation and interference matters, provides legal opinions regarding patents and manages a diverse portfolio of patent applications.

Michael represents a broad range of life sciences clients from large established companies such as Schering Plough to research institutions such as the National Institutes of Health. Michael also represents a number of venture capital firms and venture capital funded start-up companies.

Michael chairs the SoCalBio annual investor conference targeting early stage life sciences companies.

Michael leads Perkins Coie's effort to establish a life sciences-focused practice in China. Michael has chaired panel discussions on China and introduced the Chinese delegation to BIO 2004, 2005 and 2006. Michael is frequently invited to speak and write about China-related IP matters.

Education

- Loyola Law School, Los Angeles, J.D., cum laude, Order of the Coif, 1989
- University of California, Los Angeles, B.S., Biology, 1985

12^h SoCalBio Investor & Partnership Conference

Speakers & Breakout Session Panelists

Allan Wolfe, M.D.
Former General Partner
UV Partners

Allan Wolfe served as a General Partner of UV Partners since 1989. In 1983 he co-founded Hambrecht & Quist's Life Science Ventures. Earlier, Dr. Wolfe was an operating manager in startup and mature medical companies, including American Hospital Supply Corporation's principal manufacturing division where his responsibilities encompassed strategic and operating planning, research and development, manufacturing, engineering, and international marketing.

Dr. Wolfe holds a BA in American Civilization from Cornell University and a Doctor of Medicine from the New York University School of Medicine. His post graduate training included service as an intern, resident and Chief Resident in medicine and a research fellowship in cardiology and rheumatic diseases.

Dr. Wolfe is a member of the Board of Directors of the Southern California Biomedical Council.